FDA Withdraws Draft Guidance on CBD Enforcement Policy

After the Biden administration released a memo on Jan. 20 to all federal agencies informing them of a “regulatory freeze pending review,” the U.S. Food and Drug Administration (FDA) withdrew its “Cannabidiol Enforcement Policy; Draft Guidance for Industry.” Before it was withdrawn, the guidance was at the Office of Management and Budget (OMB) awaiting review. In ...